Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, Life Tech, and More

Premium

Title: Methods for Normalizing and for Identifying Small Nucleic Acids

Patent Number: 8,741,569

Filed: Oct. 23, 2009

Lead Inventor: Kai Lao, Applied Biosystems (Life Technologies)


Title: PHD2 Inhibition for Blood Vessel Normalization and Uses Thereof

Patent Number: 8,741,862

Filed: Jan. 20, 2010

Lead Inventor: Peter Carmeliet, Life Science Research Partners


Title: Compositions and Methods for Inhibiting Expression of Transthyretin

Patent Number: 8,741,866

Filed: March 1, 2012

Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals


Title: RNA Sequence-specific Mediators of RNA Interference

Patent Number: 8,742,092

Filed: March 1, 2012

Lead Inventor: Thomas Tuschl, Max Planck Institute


Title: Methods of Novel Therapeutic Candidate Identification through Gene Expression Analysis in Vascular-related Diseases

Patent Number: 8,741,861

Filed: March 27, 2009

Inventor: David Mann, Vascular Biosciences


Title: Panel of microRNAs that Silence the MCL-1 Gene and Sensitize Cancer Cells to ABT-263

Patent Number: 8,742,083

Filed: Dec. 23, 2010

Lead Inventor: Dimitri Semizarov, AbbVie

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.